Advanced Softgel Solutions for Complex Molecules
Softgels are one of the most versatile and patient-preferred dosage formats in modern medicine - especiallly for poorly soluble, mositure-sensitive, oxidation-prone, and high-potency APIs. As Ireland's only pharmaceutical softgel manufacturer, and one of the a few in Europe, Eirgen provides a specialized, rapid, and globally compliant pathway from early formulation through commercial supply.
Our platform combines deep formulation science, purpose-built high-containment infrastructure, and an accelerated development model, enabling partners to bring challenging softgel products to market with greater stability, performance, and speed.
Why Softgels?
A versatile, patient-preferred dosage form for complex small molecules.
Enhanced Solubility & Absorption
Improves solubility and boosts absorption for poorly water-soluble molecules.
Patient-Preferred Format (Easy Swallow)
Offers easy swallowing and high patient acceptance for better adherence.
Protects Sensitive APIs (Moisture, Oxidation, Light)
Safeguards moisture-, light-, and oxidation-sensitive APIs for greater stability.
Precise Dosing & Uniformity
Delivers consistent fill weight and dose accuracy across every capsule.
Improves Bioavailability &
PK Profile
Optimizes drug uptake through lipid-based and tailored fill systems.
Accelerates Early Development & POC
Fast-tracks formulation and proof-of-concept for complex small molecules.
High-Potency & Cytotoxic Friendly
Enables safe, contained delivery of high-potency and cytotoxic compounds
Supports Lifecycle Management
Ideal for reformulations, line extensions, and market differentiation.
Eirgen Softgel Expertise
Our scientists, engineers, and analytical teams specialize in delivering high-potency, moisture-sensitive and complex softgel formulations using advanced capsule shell engineering and stabilization systems.
​​
​​
High-Potency Containment
Advanced Capsule Engineering
Stability & Bioavailability Enhancement
Technical Capabilities
Our softgel capability is built on high-containment engineering, advanced formulation design, and continuous in-process control - enabling Eirgen to reliably deliver complex, high-potency softgels with stability, precision, and predictable scalability.
Accelerated Development & Commercialization
PREFORMULATION
Early feasibility, API assessment, & solubility pathways
PROTOTYPE DEVELOPMENT
Formulation options, shell design, & compatibility trials
PILOT-SCALE TRIALS
Process optimization with PAT & controlled parameters
GMP SCALE-UP
High-containment lines = validated, reproducible output
COMMERCIAL MANUFACTURING
Globally aligned supply with FDA/EMA/ PMDA-ready
systems
Performance at a Glance
3.5 Months
Development ->
Submission Batch
Accelerated execution for rapid regulatory filing.
500% Increase
Throughput Expansion
(2024 - 2025)
Significant boost in softgel capacity via engineered process optimization.
8 Months
Concept -> Commercial Supply
Proven ability to fast-track complex softgel programs.
Operational &
Market Impact
Eirgen's rapid scale-up and operational maturity have transformed its softgel platform into a reliable, high-capacity solution for partners targeting complex small-molecule markets. ​
-
500% throughput increase (2024-2025)
-
Multiple new long-term client partnerships
-
Expansion into new therapeutic areas via softgel innovation
-
Faster release cycles enabled by inline analytics
-
Strengthened global position as a high-potency softgel CDMO